Developing, executing and managing the transformation, analysis and submission of clinical research data with SAS® Drug Development
“The medical product development process is no longer able to keep pace with basic scientific innovation.” Those are harsh words, especially coming from the U.S. Food and Drug Administration (Challenge and Opportunity on the Critical Path for New Medical Products, FDA, March 2004). Discovery organizations are identifying a lot of promising compounds, but clinical research processes haven’t kept pace with timely testing of all those potential therapies. The FDA’s Critical Path Initiative makes it clear—it is time for innovation. Read more of this white paper.